CoChat
Sign Up
Cited by 126

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists

Pérez-Jeldres, Tamara, Tyler, Christopher J., Boyer, Joshua D., Karuppuchamy, Thangaraj, Yarur, Andrés, Giles, Daniel A., Yeasmin, Shaila, Lundborg, Luke, Sandborn, William J., Patel, Derek R., Rivera-Nieves, Jesús·2019·Frontiers in Pharmacology
DOI 10.3389/fphar.2019.00212PMC PMC6425155
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2019.00212

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Small molecule therapeutics may offer advantages over biologics due to their lower immunogenic and cost-effectiveness.

    “In the setting of aging and chronic disease, small molecule therapeutics may offer advantages over biologics due to their lower immunogenic and cost-effectiveness.43,44”

    From TERT activation targets DNA methylation and multiple aging hallmarks (2024) · cites this paper as [43]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Inflammatory bowel disease

    Abraham, C., & Cho, J. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804647 · Cited by 2,712 · cited 4×

    “Inflammatory Bowel diseases (IBDs) is a chronic immunemediated condition of the gastrointestinal tract (Abraham and Cho, 2009).”
    BackgroundInfluential

Flagged first, then by citations

Research works printed but not linked: 106

  1. Abbas, Cellular and Molecular Immunology. Chapter 3.
  2. Abbas, Cellular and Molecular Immunology. Chapter 7.
  3. Abbas, Cellular and Molecular Immunology. Chapter 10.
  4. Abbas, Cellular and Molecular Immunology. Chapter 15.
  5. Banerjee, 2017, JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects., Drugs, 77, 521, 10.1007/s40265-017-0701-9 · DOI · Paper page
  6. Barroso, 2017, A case of series on patients on tofacitinib in combinaton with a biologic., J. Clin. Rheumatol., 24, 349, 10.1097/RHU.0000000000000663 · DOI
  7. Beattie, 2018, P069 TD-1473, a Novel, Potent, and Orally Administered, GI-Targeted, Pan-Janus Kinase (JAK) Inhibitor.
  8. Berger, 2018, Progressive multifocal leukoencephalopathy after fingolimod treatment., Neurology, 90, e1815, 10.1212/WNL.0000000000005529 · DOI
  9. Boland, 2017, Janus kinase antagonists and other novel small molecules for the treatment of crohn’s disease., Gastroenterol. Clin. North Am., 46, 627, 10.1016/j.gtc.2017.05.015 · DOI
  10. Charles-Schoeman, 2015, Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib., Arthritis Rheumatol., 67, 616, 10.1002/art.38974 · DOI
  11. Clark, 2013, Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases., J. Med. Chem., 57, 5023, 10.1021/jm401490p · DOI
  12. NCT01375179. A Multi-centre, Double-blind, Placebo Controlled, Parallel Group, Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of KRP203 in Subjects With Moderately Active Refractory Ulcerative Colitis.
  13. NCT01563302. Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to PAtients with Advanced Cancers.
  14. NCT02378688. Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn’s Disease.
  15. NCT02389790. Extension Study of MT-1303 in Subjects With Crohn’s Disease.
  16. NCT02535689. Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus
  17. NCT02818686. TD-1473 for Active Ulcerative Colitis (UC).
  18. NCT02819635. A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis (UC).
  19. NCT02914522. Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis (SELECTION1).
  20. NCT02914535. Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis (SELECTIONLTE).
  21. NCT02914600. Filgotinib in Long-Term Extension Study of Adults With Crohn’s Disease (DIVERSITYLTE)
  22. NCT02958865. Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects with Moderate to Severe Ulcerative Colitis.
  23. NCT03006068. A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis (UC).
  24. NCT03046056. Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn’s Disease (SBCD).
  25. NCT03100942.Safety and Efficacy Study of Filgotinib, GS-9876 and Tirabrutinib in Adults With Active Sjogren’s Syndrome, 25
  26. NCT03345836. A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn’s Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy.
  27. NCT03345849. A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn’s Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have.
  28. NCT03395184. Study to Evaluate the Efficacy and Safety of Oral PF-06651600 And PF-06700841 In Subjects with Moderate to Severe Crohn’s Disease.
  29. NCT03624959. Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A.
  30. Cohen, 2018, Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis., Rheumatol. Ther., 5, 283, 10.1007/s40744-018-0097-3 · DOI
  31. Currò, 2017, Frontiers in drug research and development for inflammatory bowel disease., Front. Pharmacol., 8, 10.3389/fphar.2017.00400 · DOI
  32. Daniel, 2007, FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells., J. Immunol., 178, 2458, 10.4049/jimmunol.178.4.2458 · DOI
  33. Degagné, 2014, Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs., J. Clin. Invest., 124, 5368, 10.1172/JCI74188 · DOI
  34. Deguchi, 2006, The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice., Oncol. Rep., 16, 699, 10.3892/or.16.4.699 · DOI
  35. Dienz, 2009, The effects of IL-6 on CD4 T cell responses., Clin. Immunol., 130, 27, 10.1016/j.clim.2008.08.018 · DOI
  36. Divito, 2014, Inhibiting Janus kinases to treat alopecia areata., Nat. Med., 20, 989, 10.1038/nm.3685 · DOI
  37. Dowty, 2014, The pharmacokinetics, metabolism and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans., Drug Metab. Dispos., 42, 759, 10.1124/dmd.113.054940 · DOI
  38. 2018, FDA. FDA Drug Safety Communication: FDA Warns About Cases of Rare Brain Infection with MS Drug Gilenya (fingolimod) in Two Patients With no Prior Exposure to Immunosuppressant Drugs.
  39. Feagan, 2017, P1272 - Endoscopic and Clinical Efficacy Demonstrated With Oral Ozanimod in Moderately to Severely Active Crohn’s Disease. WCG at ACG.
  40. Flamant, 2017, Advances in the development of janus kinase inhibitors in inflammatory bowel disease: future prospects., Drugs, 77, 1057, 10.1007/s40265-017-0755-8 · DOI
  41. Gonzalez-Cabrera, 2014, S1P signaling: new therapies and opportunities., F1000 Prime Rep., 6, 10.12703/P6-109 · DOI
  42. Hemperly, 2018, Clinical pharmacology in adult and pediatric inflammatory bowel disease., Inflamm. Bowel Dis., 10.1093/ibd/izy189 · DOI
  43. Horga, 2008, FTY720 (fingolimod) for relapsing multiple sclerosis., Expert Rev. Neurother., 8, 699, 10.1586/14737175.8.5.699 · DOI
  44. Hornung, 2014, Remission of recalcitrant dermatomyositis treated with ruxolitinib., N. Engl. J. Med., 371, 1324, 10.1056/NEJMc1412997 · DOI
  45. Hsu, 2014, JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis., J. Immunol. Res., 2014, 10.1155/2014/283617 · DOI
  46. Hu, 2009, Cross-regulation of signaling and immune responses by IFN-γ and STAT1., Immunity, 31, 539, 10.1016/j.immuni.2009.09.002 · DOI · Paper page
  47. Huang, 2016, Sphingosine-1-phosphate phosphatase 2 promotes disruption of mucosal integrity and contributes to ulcerative colitis in mice and humans., FASEB J., 30, 2945, 10.1096/fj.201600394R · DOI
  48. Huwiler, 2018, The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: recent findings and new perspectives., Pharmacol. Ther., 185, 34, 10.1016/j.pharmthera.2017.11.001 · DOI
  49. Jabeen, 2015, Altered STAT4 isoform expression in patients with inflammatory bowel disease., Inflamm. Bowel Dis., 21, 2383, 10.1097/MIB.0000000000000495 · DOI
  50. Jatiani, 2010, JAK/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies., Genes Cancer, 1, 979, 10.1177/1947601910397187 · DOI
  51. Kang, 2018, Cardiovascular safety of biologics and JAK inhibitors in patients with rheumatoid arthritis., Curr. Rheumatol. Rep., 20, 10.1007/s11926-018-0752-2 · DOI
  52. Kimura, 2009, The transcription factors STAT5A/B regulate GM-CSF-mediated granulopoiesis., Blood, 114, 4721, 10.1182/blood-2009-04-216390 · DOI
  53. Kornbluth, 2010, Practice parameters committee of the american college of gastroenterology., Am. J. Gastroenterol., 105, 501, 10.1038/ajg.2009.727 · DOI
  54. Le Stunff, 2004, Generation and metabolism of bioactive sphingosine-1-phosphate., J. Cell. Biochem., 92, 882, 10.1002/jcb.20097 · DOI
  55. Levy, 2015, Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate., J. Am. Acad. Dermatol., 73, 395, 10.1016/j.jaad.2015.06.045 · DOI
  56. Lichtenstein, 2017, Tofacitinib, an oral Janus Kinase inhibitor, in the treatment of ulcerative colitis: open-label, long-term extension study., United Eur. Gastroenterol. J., 5, A39, 10.1016/j.cgh.2018.11.035 · DOI
  57. Lichtenstein, 2018, ACG clinical guideline: management of crohn’s disease in adults., Am J Gastroenterol., 113, 481, 10.1038/ajg.2018.27 · DOI
  58. Liu, 2017, Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure., J. Am. Acad. Dermatol., 77, e1, 10.1016/j.jaad.2017.05.043 · DOI
  59. Mahadevan, 2018, Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis., Inflamm. Bowel Dis., 10.1093/ibd/izy160 · DOI
  60. Miklossy, 2013, Therapeutic modulators of STAT signalling for human diseases., Nat. Rev. Drug Discov., 12, 611, 10.1038/nrd4088 · DOI
  61. Mizushima, 2004, Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis., Inflamm. Bowel Dis., 10, 182, 10.1097/00054725-200405000-00002 · DOI
  62. Montor, 2018, Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors., Mol. Cancer, 17, 1, 10.1186/s12943-018-0792-2 · DOI
  63. Montrose, 2013, S1P1 localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity., J. Lipid Res., 54, 843, 10.1194/jlr.M034108 · DOI
  64. Murphy, 2015, Small molecule drugs with immunomodulatory effects in cancer., Hum. Vaccin. Immunother., 11, 2463, 10.1080/21645515.2015.1057363 · DOI
  65. Olivera, 2016, Next generation of small molecules in inflammatory bowel disease., Gut, 66, 199, 10.1136/gutjnl-2016-312912 · DOI · Paper page
  66. Olivera, 2017, JAK inhibition in inflammatory bowel disease., Expert Rev. Clin. Immunol., 13, 693, 10.1080/1744666X.2017.1291342 · DOI
  67. Ordás, 2012, Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms., Clin. Pharmacol. Ther., 91, 635, 10.1038/clpt.2011.328 · DOI
  68. Panes, 2017, New treatment strategies for ulcerative colitis., Expert Rev. Clin. Immunol., 13, 963, 10.1080/1744666X.2017.1343668 · DOI
  69. Panés, 2017, Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials., Gut, 66, 1049, 10.1136/gutjnl-2016-312735 · DOI
  70. Park, 2017, Sphingosine 1-phosphate receptor modulators and drug discovery., Biomol. Ther., 25, 80, 10.4062/biomolther.2016.160 · DOI
  71. Pelletier, 2012, Fingolimod for multiple sclerosis., N. Engl. J. Med., 366, 339, 10.1056/NEJMct1101691 · DOI
  72. Perez-Jeldres, 2018, Cell trafficking interference in inflammatory bowel disease: therapeutic interventions based on pathogenesis concepts., Inflamm. Bowel Dis., 10.1093/ibd/izy269 · DOI
  73. Pettus, 2003, The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha., FASEB J., 17, 1411, 10.1096/fj.02-1038com · DOI
  74. Peyrin-Biroulet, Modulation of sphingosine-1-phosphate in inflammatory bowel disease., Autoimmun. Rev., 16, 495, 10.1016/j.autrev.2017.03.007 · DOI
  75. Peyrin-Biroulet, Safety, Tolerability and Lymphocyte-Lowering Properties of Etrasimod (APD334), an Oral, Potent, Next-Generation, Selective S1P Receptor Modulator, After Dose Escalation in Healthy Volunteer.
  76. 2018, Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis.
  77. Radeke, 2016, P372. A multicentre, double-blind, placebo-controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of the S1P receptor modulator KRP203 in subjects with moderately active refractory ulcerative colitis., J. Crohn’s Colitis, 10, S285
  78. Radi, 2011, Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBS-induced Crohn’s disease model., Dig. Dis. Sci., 56, 2283, 10.1007/s10620-011-1628-8 · DOI
  79. Samanen, 2013, “Similarities and differences in the discovery and use of biopharmaceuticals and small-molecule chemotherapeutics,” in, Introduction to Biological and Small Molecule Drug Research and Development: Theory and Case Studies, 10.1016/B978-0-12-397176-0.00005-4 · DOI
  80. Sanchez, 2004, Structural and functional characteristics of S1P receptors., J. Cell. Biochem., 92, 913, 10.1002/jcb.20127 · DOI
  81. Sandborn, The Intestinally Restricted, Orally Administered, Pan-Jak Inhibitor TD-1473 Demonstrate Favorable Safety, Tolerability, Pharmacokinetics, and Signal for Clinical Activity in Subjects With Moderately-to-Severely Active Ulcerative Colitis.
  82. Sandborn, Safety and efficacy of ABT-494 (Upadacitinib), an oral jak1 inhibitor, as induction therapy in patients with crohn’s disease: results from Celest., Gastroenterology, 152, S1308, 10.1016/S0016-5085(17)34357-3 · DOI
  83. Sandborn, 2016, Ozanimod induction and maintenance treatment for ulcerative colitis., N. Engl. J. Med., 374, 1754, 10.1056/NEJMoa1513248 · DOI
  84. Sandborn, Efficacy and Safety of Upadacitinib as an Induction Therapy For Patients With Moderately-to Severely Active Ulcerative Colitis: Data From the Phase 2B Study U-ACHIEVE.
  85. Sandborn, 2014, A phase 2 study of Tofacitinib, an oral janus kinase inhibitor, inpatients with crohn’s disease., Clin. Gastroenterol. Hepatol., 12, e2, 10.1016/j.cgh.2014.01.029 · DOI
  86. Sandborn, Tofacitinib as induction and maintenance therapy for ulcerative colitis., N. Engl. J. Med., 376, 1723, 10.1056/NEJMoa1606910 · DOI
  87. Sandborn, 2012, Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis., New Engl. J. Med., 367, 616, 10.1056/NEJMoa1112168 · DOI
  88. Sands, 2018, Peficitinib, an oral janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomized, phase 2 study., J. Crohns Colitis, 10.1093/ecco-jcc/jjy085 · DOI
  89. Schwartz, 2017, JAK inhibition as a therapeutic strategy for immune and inflammatory diseases., Nat. Rev. Drug Discov., 16, 843, 10.1038/nrd.2017.201 · DOI · Paper page
  90. Scott, 2016, Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity., Br. J. Pharmacol., 173, 1778, 10.1111/bph.13476 · DOI
  91. 2018, My 2 Cents On the Ozanimod Saga.
  92. Shirakabe, 2018, Amelioration of colitis through blocking lymphocytes entry to Peyer’s patches by sphingosine-1-phosphate lyase inhibitor., J. Gastroenterol. Hepatol., 10.1111/jgh.14092 · DOI
  93. Snider, 2009, A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis., FASEB J., 23, 143, 10.1096/fj.08-118109 · DOI
  94. Soendergaard, 2018, Targeting JAK-STAT signal transduction in IBD., Pharmacol. Ther., 192, 100, 10.1016/j.pharmthera.2018.07.003 · DOI
  95. Vanhoutte, 2017, Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective Janus kinase 1 inhibitor, after short-term treatment of rheumatoid arthritis: results of two randomized Phase IIA trials., Arthritis Rheumatol., 69, 1949, 10.1002/art.40186 · DOI
  96. Verden, 2018, Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors., Drug Saf., 41, 357, 10.1007/s40264-017-0622-2 · DOI
  97. Vermeire, Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial., Lancet, 389, 266, 10.1016/S0140-6736(16)32537-5 · DOI · Paper page
  98. Vermeire, Effect of disease duration and location on clinical remission in Crohn’s disease patients treated with Filgotinib, a selective JAK1 inhibitor: post-hoc analysis from the phase 2 FITZROY study., United Eur. Gastroenterol. J., 5, A1
  99. Villarino, 2015, Mechanisms of Jak/STAT signaling in immunity and disease., J. Immunol., 194, 21, 10.4049/jimmunol.1401867 · DOI
  100. Villarino, 2017, Mechanisms and consequences of Jak-STAT signaling in the immune system., Nat. Immunol., 18, 374, 10.1038/ni.3691 · DOI · Paper page
  101. White, 2018, Review article: novel oral-targeted therapies in inflammatory bowel disease., Aliment. Pharmacol. Ther., 47, 1610, 10.1111/apt.14669 · DOI
  102. Winthrop, 2017, The emerging safety profile of JAK inhibitors in rheumatic disease., Nat. Rev. Rheumatol., 13, 234, 10.1038/nrrheum.2017.23 · DOI
  103. Wollny, 2017, Sphingosine-1-phosphate metabolism and its role in the development of inflammatory bowel disease., Int. J. Mol. Sci., 18, 10.3390/ijms1804074 · DOI
  104. Yarur, 2015, Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases., Inflamm. Bowel Dis., 21, 1709, 10.1097/MIB.0000000000000380 · DOI
  105. Zhang, 2018, Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis., Circulation, 137, 1934, 10.1161/CIRCULATIONAHA.117.030423 · DOI
  106. Zhou, 2007, IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways., Nat. Immunol., 8, 967, 10.1038/ni1488 · DOI

Cited by

Sorted by citations

Metadata

Authors
Pérez-Jeldres, T., Tyler, C. J., Boyer, J. D., Karuppuchamy, T., Yarur, A., Giles, D. A., Yeasmin, S., Lundborg, L., Sandborn, W. J., Patel, D. R., & Rivera-Nieves, J.
Venue
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Published
2019-03-13
Volume
10
ISSN
1663-9812
DOI
10.3389/fphar.2019.00212
PMC
PMC6425155
Cited by
126
References
1
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
National Institutes of Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review